Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News MSD hosts Annual Business Briefing

MSD hosts Annual Business Briefing

12th December 2007

Merck, Sharp and Dohme (MSD) has hosted its Annual Business Briefing where the company reviewed its progress under a new strategic plan designed to change the way MSD develops and distributes its products worldwide.

Since 2005, the company has been developing and implementing a new operating model where customer focus drives drug discovery, development and marketing.

Speaking at the briefing, MSD chairman, president and chief executive officer Richard T Clark confirmed that the company was realising the benefits of the strategy’s successful execution.

“As a result, Merck has a sustainable business model that will allow us to realise the goals we set for 2010 and to position the company for future success,” he stated.

Mr Clark went on to outline some of the goals MSD had met or expects to meet by 2010.

He illustrated that Merck’s pipeline had continued to make progress with seven products now in phase III development as well as the company expecting to file applications for expanded indications for Gardasil and Isentress in 2008.

Kenneth C Frazier, executive vice-president and president at Global Human Health also told analysts and investors that successful early launches of Gardasil, Januvia, Janumet and Isentress had reflected better alignment of product development and commercialisation efforts.

Last month, MSD announced the appointment of Thomas H Glocer, the chief executive of Reuters Group, to the company’s board of directors.

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.